Perrigo Company plc (PRGO) to Distribute Quarterly Dividend of $0.29 on March 24th

Perrigo Company plc (NYSE:PRGO) announced a quarterly dividend on Thursday, February 19th. Investors of record on Monday, March 2nd will be given a dividend of 0.29 per share on Tuesday, March 24th. This represents a c) dividend on an annualized basis and a yield of 8.8%. The ex-dividend date is Monday, March 2nd.

Perrigo has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 23 consecutive years. Perrigo has a dividend payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Perrigo to earn $3.06 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 37.9%.

Perrigo Trading Down 6.8%

PRGO traded down $0.97 during midday trading on Friday, hitting $13.23. 5,758,243 shares of the company were exchanged, compared to its average volume of 2,470,793. The firm’s 50 day moving average price is $14.41 and its 200-day moving average price is $17.49. Perrigo has a 1-year low of $12.17 and a 1-year high of $30.93. The firm has a market capitalization of $1.82 billion, a P/E ratio of -1.29, a P/E/G ratio of 1.27 and a beta of 0.39. The company has a quick ratio of 1.44, a current ratio of 2.51 and a debt-to-equity ratio of 0.81.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 8.62% and a negative net margin of 33.51%.The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the business earned $0.93 earnings per share. Perrigo’s revenue was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts forecast that Perrigo will post 2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Perrigo

A number of institutional investors have recently modified their holdings of the company. Amundi raised its holdings in Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares in the last quarter. United Services Automobile Association acquired a new position in Perrigo during the 1st quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after purchasing an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.